Senesco Logo
Home About Us News and Media Our Technologies Clinical Development Commercialization Investor Relations Contact Us
   
  Senesco is a therapeutics company employing its strong proprietary platforms in gene regulation and antibody engineering. The Company's lead therapeutic candidate SNS01-T incorporates recent developments in siRNA, gene therapy and nanotechnology. Senesco is building its portfolio with other applications for SNS01-T in cancer and inflammation, as well as several monoclonal antibody therapeutic candidates.
  Clinical Trials  
  Senesco is sponsoring a Phase 1b/2a clinical trial of SNS01-T for patients with multiple myeloma who have relapsed from, or failed to respond to, at least two previous treatment regimens. For contact information, please visit the study page on clinicaltrials.gov.


 
 
2014-6-25
Senesco Announces New CEO
 
2014-6-25
Senesco Presents Company Update at 2014 BIO International Convention
 
2014-6-19
Senesco to Update on R&D Plans at BIO
 
  Disclaimer.
facebook twitter youtube google+ linkedin